Latest News for: pd-l1

Edit

Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint

PR Newswire 15 Jul 2026
This strategy is expected to unlock the therapeutic potential of the PD-1 mAb in patients with PD-L1-negative or limited immune responses, breaking this therapeutic bottleneck ... of PD-L1-negative NSCLC.
Edit

Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), ...

The Eagle-Tribune 14 Jul 2026
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jul 14, 2026-- ... .
Edit

Minister taking 'Thatcher' approach to legal aid fee row - Gannon

RTE 14 Jul 2026
Social Democrats TD Gary Gannon has likened Minister for Justice Jim O'Callaghan to "Margaret Thatcher in the 1980s" amid the dispute over the new legal aid payments scheme ... The new system replaces that with a €520 flat fee ... .
Edit

Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC

PR Newswire 10 Jul 2026
Opamtistomig (LBL-024) is emerging as a next-generation pan-cancer backbone therapy with potential overall survival (OS) benefit that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB.
Edit

PD-L1 Inhibitors Market Size Expected to Witness Significant Growth by 2034, estimates DelveInsight

GetNews 03 Jul 2026
DelveInsight's "PD-L1 Inhibitors Market Insight, Epidemiology and Market Forecast – 2034" report delivers an in-depth analysis of PD-L1 inhibitors epidemiology, market, and clinical development, ...
Edit

Treos Bio Presents New Translational Data Showing PolyPEPI1018 Plus Anti-PD-L1 Immunotherapy Remodels the Tumor Immune ...

Nasdaq Globe Newswire 02 Jul 2026
ESMO GI poster highlights increased intratumoral CD8+ T-cell ...
Edit

Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC

PR Newswire 02 Jul 2026
Lumipodlin selectively binds to the PD-L1 receptor and induces its internalization from the cell surface, effectively inhibiting the PD-1/PD-L1 interaction and alleviating PD-L1-mediated suppression of T-cell activation.
Edit

2027 NBA Mock Draft: Tyran Stokes, Jordan Smith Jr. lead an early look at top ...

CBS Sports 29 Jun 2026
The 2026 NBA Draft cycle is officially in the books, so that means it's time to look at the next cycle of talent that we will be talking about for the next 12 months ... 5 and the middle of the first round was minimal ... 3 overall after finishing as the No.
Edit

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC) (Merck & Co Inc)

Public Technologies 25 Jun 2026
KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Edit

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer

PR Newswire 22 Jun 2026
This patent will expand on the previously granted patents for REQORSA in combination with PD-1 and PD-L1 antibodies, which have been granted in the U.S., Japan, Mexico, Russia, Chile, China, Singapore Europe, Korea, Australia and Israel.
Edit

James Slipper answers SOS for coach Joe Schmidt’s last three Wallabies Tests

The Observer 19 Jun 2026
Veteran prop James Slipper and uncapped trio Declan Meredith, Lachlan Shaw and Miles Amatosero have all been included in the Wallabies squad for next month’s Nations Championship Tests in Australia ... ‘The present is all you have’ ... Read more ... Share ... .
Edit

Triathlon and Tradition at Mighty Montauk

The East Hampton Star 18 Jun 2026
On Saturday, the Robert J. Aaron Memorial Mighty Montauk Triathlon celebrated its 45th anniversary, with a field of 374 athletes and a familiar face crossing the finish line first ... “It’s a delight to come back here and kick off the summer ... .
Edit

PD-L1 Biomarker Testing Market to Reach USD 1,830.7 Million by 2036 as Precision Oncology and Immunotherapy Adoption Accelerate Global Demand

PR Newswire 16 Jun 2026
The PD-L1 biomarker testing market is transitioning from conventional oncology diagnostics toward highly specialized biomarker-based testing platforms that support personalized immunotherapy decisions.
Edit

Replay: WIAA state softball recap, scores for championship games

Oshkosh Northwestern 14 Jun 2026
Hamilton wins first WIAA state softball title. Hamilton players Aubrie Peterson and Bitsy Palicka talk about their team's 8-3 victory over Muskego in the WIAA Division 1 state softball title game ... Almond-Bancroft 16, Belmont 8Division 4 championship.
Edit

PD-1 and PD-L1 Inhibitors Market is Expected to Witness Robust Growth by 2034, Estimates DelveInsight

GetNews 10 Jun 2026
Interested to know which PD-1 and PD-L1 inhibitor therapies will capture the highest market share?. Download the report to understand the latest PD-1 and PD-L1 inhibitors market trends and forecasts - ... PD-1 and PD-L1 Inhibitors Market Overview.

Article Search

tools
×
×
×
×